Clinical consequences of polymorphic acetylation of basic drugs

摘要: The clinical consequences (therapeutic and toxic) of drug acetylation polymorphism are reviewed for procainamide, hydralazine, phenelzine, isoniazid, salicylazosulfapyridine. Genetic slow acetylators more likely than rapid to experience the following adverse reactions: (1) earlier development procainamide-induced antinuclear antibody; (2) frequent systemic lupus erythematosus (SLE); (3) hydralazine-induced SLE; (4) spontaneous (5) drowsiness nausea from phenelzine; (6) cyanosis, hemolysis, transient reticulocytosis salicylazosulfapyridine; (7) polyneuropathy after isoniazid therapy. incidence hepatitis may, however, be common in acetylators. also greater therapeutic responses similar doses following: hydralazine provided beta blockers concurrently used, if once weekly therapy is used. Thus, knowledge acetylator phenotype a patient can help determine relative risk some drug-related toxic responses.